Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly

Clinical article

Restricted access

Object

Acromegaly, a syndrome of excess growth hormone (GH) secretion typically caused by a GH-secreting pituitary adenoma, reduces life expectancy by approximately 10 years when left untreated. Treatment of acromegaly involves combinations of one or more discrete therapeutic modalities to achieve biochemical control. Unfortunately, data capable of informing decisions among alternate management strategies are presently lacking.

Methods

The authors performed a comparative effectiveness research (CER) review integrating efficacy, cost, and quality of life (QOL) analysis for treatment strategies comprising various combinations of surgery, radiotherapy, stereotactic radiosurgery, and pharmacotherapy in patients with acromegaly caused by a pituitary microadenoma. A management decision tree was used to identify 5 treatment strategies, each with up to 4 potential treatment steps. Efficacy was assessed using recent literature reports of biochemical control rates for each modality. Cost estimations were derived from wholesale drug prices and from the Healthcare Cost and Utility Project. Quality of life data were obtained from studies utilizing the Acromegaly Quality of Life Questionnaire.

Results

Individual treatment modalities were analyzed and ranked in each of 3 domains: highest rate of success, lowest cost, and highest QOL, and these scores were combined to facilitate comparison of overall effectiveness of each of the management strategies. These aggregate effectiveness scores were used to compare the 5 strategies from the decision tree, and a novel strategy was also proposed.

Conclusions

The choice of management strategy must be individualized for each patient with acromegaly. This CER analysis provides a comprehensive framework to inform clinical decisions among alternate management strategies in patients with GH-secreting pituitary microadenomas.

Abbreviations used in this paper:AcroQoL = Acromegaly Quality of Life Questionnaire; AWP = average wholesale price; CER = comparative effectiveness research; GH = growth hormone; HCUP = Healthcare Cost and Utility Project; IGF-1 = insulin-like growth factor–1; LAR = long-acting repeatable; SRS = stereotactic radiosurgery.

Article Information

* Dr. Marko and Ms. LaSota contributed equally to this work

Address correspondence to: Nicholas F. Marko, M.D., Cancer Research UK Cambridge Research Institute, Cambridge, CB2 0RE United Kingdom. email: nmarko@gmail.com.

Please include this information when citing this paper: published online June 22, 2012; DOI: 10.3171/2012.4.JNS11739.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Decision tree for the treatment of GH-secreting pituitary tumors. Peg = pegvisomant; SA = somatostatin analog.

References

1

Abosch ATyrrell JBLamborn KRHannegan LTApplebury CBWilson CB: Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83:341134181998

2

Attanasio REpaminonda PMotti EGiugni EVentrella LCozzi R: Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 88:3105 31122003

3

Badia XWebb SMPrieto LLara N: Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2:132004

4

Barkan ALHalasz IDornfeld KJJaffe CAFriberg RDChandler WF: Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:318731911997

5

Barrande GPittino-Lungo MCoste JPonvert DBertagna XLuton JP: Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779 37852000

6

Bates PRCarson MNTrainer PJWass JA: Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol (Oxf) 68:1361422008

7

Beauregard CTruong UHardy JSerri O: Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86912003

8

Ben-Shlomo ASheppard MCStephens JMPulgar SMelmed S: Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14:2842942011

9

Bevan JSAtkin SLAtkinson ABBouloux PMHanna FHarris PE: Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:455445632002

10

Biermasz NRRoelfsema FPereira AMRomijn JA: Costeffectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res 9:2232342009

11

Biermasz NRvan Dulken HRoelfsema F: Long-term followup results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 85:247624822000

12

Biermasz NRvan Dulken HRoelfsema F: Ten-year followup results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 85:459646022000

13

Biermasz NRvan Thiel SWPereira AMHoftijzer HCvan Hemert AMSmit JW: Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89:536953762004

14

Buchfelder MSchlaffer S: Surgical treatment of pituitary tumours. Best Pract Res Clin Endocrinol Metab 23:6776922009

15

Buchfelder MWeigel DDroste MMann KSaller BBrübach K: Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161:27352009

16

Caron PBeckers ACullen DRGoth MIGutt BLaurberg P: Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:991042002

17

Caron PBex MCullen DRFeldt-Rasmussen UPico Alfonso AMPynka S: One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 60:7347402004

18

Caron PCogne MRaingeard IBex-Bachellerie VKuhn JM: Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64:2092142006

19

Castinetti FMorange IDufour HRegis JBrue T: Radiotherapy and radiosurgery in acromegaly. Pituitary 12:3102009

20

Castinetti FRégis JDufour HBrue T: Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 6:2142232010

21

Castinetti FTaieb DKuhn JMChanson PTamura MJaquet P: Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90:448344882005

22

Chanson PBoerlin VAjzenberg CBachelot YBenito PBringer J: Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 53:5775862000

23

Chanson PBorson-Chazot FKuhn JMBlumberg JMaisonobe PDelemer B: Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 69:2993052008

24

Chanson PSalenave SKamenicky PCazabat LYoung J: Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23:5555742009

25

Colao A: The importance of presurgical somatostatin analogue therapy in acromegaly. Endokrynol Pol 58:3563602007

26

Colao AAuriemma RSLombardi GPivonello R: Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247 2712011

27

Colao AFerone DMarzullo PCappabianca PCirillo SBoerlin V: Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:277927862001

28

Cozzi RBarausse MAsnaghi DDallabonzana DLodrini SAttanasio R: Failure of radiotherapy in acromegaly. Eur J Endocrinol 145:7177262001

29

Cozzi RDallabonzana DAttanasio RBarausse MOppizzi G: A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 141:2672711999

30

De PRees DADavies NJohn RNeal JMills RG: Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88:356735722003

31

Fallon Community Health Plan: Lanreotide (Somatuline Depot). Prior Authorization Approval Criteria Worcester, MAFallon Community Health Plan2008. (http://www.fchp.org/~/media/Files/FCHP/Imported/SomatulineDepot_lanreotide.pdf.ashx) [Accessed April 25 2012]

32

Fallon Community Health Plan: Octreotide (Sandostatin). Prior Authorization Approval Criteria Worcester, MAFallon Community Health Plan2008. (http://www.fchp.org/~/media/Files/FCHP/Imported/Sandostatin_octreotide.pdf.ashx) [Accessed April 25 2012]

33

Feelders RAHofland LJvan Aken MONeggers SJLamberts SWde Herder WW: Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69:220722262009

34

Feenstra Jde Herder WWten Have SMvan den Beld AWFeelders RAJanssen JA: Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:164416462005

35

Freda PUWardlaw SLPost KD: Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 89:3533581998

36

Ghaferi AA: Bending the cost curve in the United States: the role of comparative effectiveness research. Crit Care 14:1682010

37

Giustina ABarkan ACasanueva FFCavagnini FFrohman LHo K: Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:5265292000

38

Giustina ABronstein MDCasanueva FFChanson PGhigo EHo KK: Current management practices for acromegaly: an international survey. Pituitary 14:1251332011

39

Giustina AChanson PBronstein MDKlibanski ALamberts SCasanueva FF: A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:314131482010

40

Holdaway IMBolland MJGamble GD: A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89952008

41

Holdaway IMRajasoorya C: Epidemiology of acromegaly. Pituitary 2:29411999

42

Hua SCYan YHChang TC: Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 155:8318372006

43

Izawa MHayashi MNakaya KSatoh HOchiai THori T: Gamma knife radiosurgery for pituitary adenomas. J Neurosurg 93:Suppl 319222000

44

Jallad RSMusolino NRKodaira SCescato VABronstein MD: Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?. Clin Endocrinol (Oxf) 67:3103152007

45

Jallad RSMusolino NRSalgado LRBronstein MD: Treatment of acromegaly: is there still a place for radiotherapy?. Pituitary 10:53592007

46

Jallad RSMusolino NRSalgado LRBronstein MD: Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63:1681752005

47

Jenkins PJBates PCarson MNStewart PMWass JA: Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91:123912452006

48

Jenkins PJEmery MHowling SJEvanson JBesser GMMonson JP: Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Horm Res 62:2272322004

49

Jezková JMarek JHána VKrsek MWeiss VVladyka V: Gamma knife radiosurgery for acromegaly—long-term experience. Clin Endocrinol (Oxf) 64:5885952006

50

Karavitaki NTurner HEAdams CBCudlip SByrne JVFazal-Sanderson V: Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68:9709752008

51

Katznelson L: Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab 95:411441232010

52

Kauppinen-Mäkelin RSane TSintonen HMarkkanen HVälimäki MJLöyttyniemi E: Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 91:389138962006

53

Kreutzer JVance MLLopes MBLaws ER Jr: Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:407240772001

54

Laws ERVance MLThapar K: Pituitary surgery for the management of acromegaly. Horm Res 53:Suppl 371752000

55

Losa MGioia LPicozzi PFranzin AValle MGiovanelli M: The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 93:254625522008

56

Marko NFWeil RJ: An introduction to comparative effectiveness research. Neurosurgery 70:4254342012

57

Matta MPCouture ECazals LVezzosi DBennet ACaron P: Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158:3053102008

58

Melmed S: Acromegaly pathogenesis and treatment. J Clin Invest 119:318932022009

59

Melmed SColao ABarkan AMolitch MGrossman ABKleinberg D: Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:150915172009

60

Minniti GTraish DAshley SGonsalves ABrada M: Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90:8008042005

61

Moore DJAdi YConnock MJBayliss S: Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 9:202009

62

Murray RDMelmed S: A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:295729682008

63

Neggers SJde Herder WWJanssen JAFeelders RAvan der Lely AJ: Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160:5295332009

64

Neggers SJvan Aken MOde Herder WWFeelders RAJanssen JABadia X: Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93:385338592008

65

Neggers SJvan Aken MOJanssen JAFeelders RAde Herder WWvan der Lely AJ: Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92:459846012007

66

Newman CBMelmed SGeorge ATorigian DDuhaney MSnyder P: Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:303430401998

67

Nicolucci AMaione AFranciosi MAmoretti RBusetto ECapani F: Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 25:2132202008

68

Nomikos PBuchfelder MFahlbusch R: The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 152:3793872005

69

Pantanetti PSonino NArnaldi GBoscaro M: Self image and quality of life in acromegaly. Pituitary 5:17192002

70

Parkinson CBurman PMessig MTrainer PJ: Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92:1901952007

71

Pollock BEJacob JTBrown PDNippoldt TB: Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 106:833 8382007

72

Powell JSWardlaw SLPost KDFreda PU: Outcome of radiotherapy for acromegaly using normalization of insulinlike growth factor I to define cure. J Clin Endocrinol Metab 85:206820712000

73

Rowles SVPrieto LBadia XShalet SMWebb SMTrainer PJ: Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 90:333733412005

74

Scheidegger UAllemann SScheidegger KDiem P: Continuous subcutaneous insulin infusion therapy: effects on quality of life. Swiss Med Wkly 137:4764822007

75

Schreiber IBuchfelder MDroste MForssmann KMann KSaller B: Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75822007

76

Sheehan JPouratian NSteiner LLaws EVance M: Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. Clinical article. J Neurosurg 114:3033092011

77

Sherlock MAyuk JTomlinson JWToogood AAAragon- Alonso ASheppard MC: Mortality in patients with pituitary disease. Endocr Rev 31:3013422010

78

Swearingen BBarker FG IIKatznelson LBiller BMGrinspoon SKlibanski A: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:341934261998

79

T'Sjoen GBex MMaiter DVelkeniers BAbs R: Healthrelated quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol 157:4114172007

80

Trainer PJDrake WMKatznelson LFreda PUHerman-Bonert Vvan der Lely AJ: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:117111772000

81

Trepp RStettler CZwahlen MSeiler RDiem PChrist ER: Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) 147:2432512005

82

van der Lely AJHutson RKTrainer PJBesser GMBarkan ALKatznelson L: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:175417592001

83

Verhelst JAPedroncelli AMAbs RMontini MVandeweghe MVAlbani G: Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143:5775842000

84

Vik-Mo EOOksnes MPedersen PHWentzel-Larsen TRødahl EThorsen F: Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol 157:2552632007

85

Walgreens Health Initiatives: Volume 7 Number 3 March 2003 (http://www.springsgov.com/units/empservices/Benefits_2003/Walgreens_News_Mar03.pdf) [Accessed May 1 2012]

86

Webb SMBadia XSurinach NL: Spanish AcroQoL Study Group: Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155:2692772006

87

Wexler TGunnell LOmer ZKuhlthau KBeauregard CGraham G: Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 94:247124772009

88

Wu YPGraves MMRoberts MCMitchell AC: Is insulin pump therapy better than injection for adolescents with diabetes?. Diabetes Res Clin Pract 89:1211252010

89

Zhang NPan LWang EMDai JZWang BJCai PW: Radiosurgery for growth hormone-producing pituitary adenomas. J Neurosurg 93:Suppl 3692000

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 166 166 48
Full Text Views 221 221 10
PDF Downloads 121 121 7
EPUB Downloads 0 0 0

PubMed

Google Scholar